Friday, March 17, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

Critical Reagents Program Issues RFI for Biodefense Material Services

by Global Biodefense Staff
August 13, 2012

The Department of Defense Critical Reagents Program (CRP) has issued a Request for Information (RFI) seeking companies qualified to support the manufacture, storage, and distribution of high priority reagents and biological sampling kits.

The CRP’s mission is to serve as the principle resource of high quality, validated, and standardized biological detection assays and reagents that meet the requirements of the military and biological defense community by facilitating the transition of new technologies and coordinating their advanced development, efficient production and timely distribution.

These critical reagents include antibodies, inactivated antigens, genomic materials, electrochemiluminescence (ECL) assays, polymerase chain reaction (PCR) assays, lateral flow immunoassays (LFI), and biological sampling kits used for the detection of Category A and B biological warfare agents. Target pathogens include C. botulinum, B. anthracis, Burkholderia, Brucella, F. tularensis, and Y. pestis.

In addition to providing reagents for assay development and validation research, CRP supports the manufacture, storage and distribution of consumable reagents and end items for the Joint Biological Point Detection System (JBPDS) and the Joint Portal Shield (JPS) System, as well as other Hand Held Assays (HHA) and sampling kits used for domestic preparedness, Homeland Defense, and counter-terrorist operations.

The Government is interested in receiving information from qualified companies in the following areas:

-Immunoassay and reagent evaluation and testing

-Product stability and accelerated shelf life testing

-Immunoassay and reagent evaluation and testing (environmentally controlled; BSL 2)

-Verification testing on lateral flow immunoassays (LFI) including but not limited to sensitivity, false positive reactions, dose response curves, cross-reactivity to near neighbors/battlefield interferents, and physical specification inspection

-Verification testing on Electrochemiluminescence (ECL) assays including, but not limited to, signal to noise ratio, sensitivity, and false positive ration

-Verification testing on ECL system reagents including but not limited to pH, appearance, surfactant concentration, physical inspection, conductivity, and hypochlorite testing

-Testing on ECL positive controls to verify controls perform within acceptable ranges based on conformance criteria

This is a Request for Information (RFI) for planning purposes only. The Government solicitation, planned for release in 2013, will have an estimated dollar value of no more than $2M over a two-year period.

Full details are available under Solicitation Number: W911QY-12-S-0010. The response deadline is September 10, 2012.

Tags: AnthraxBotulinum NeurotoxinBrucellaBurkholderiaF. tularensisJPEO-CBRNDRFI

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks
Pathogens

NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks

December 7, 2022
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy